Shandong Lukang Pharmaceutical operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Lukang Pharmaceutical with three other
companies in this sector in China:
Shenzhen Hepalink Pharmaceutical Company Limited
sales of 2.26 billion Chinese Renmimbi [US$331.31 million]
of which 100%
was Pharmaceutical Manufacturing),
Zhejiang Jianfeng Group Company Limited
(2.38 billion Chinese Renmimbi [US$348.80 million]
of which 45%
was Pharmaceutical), and
ChangChun High New Technology Industries
(2.87 billion Chinese Renmimbi [US$421.40 million]
of which 81%
During the year ended December of 2016, sales at
Shandong Lukang Pharmaceutical were 2.51 billion Chinese Renmimbi (US$367.34 million).
increase of 4.0%
versus 2015, when the company's sales were 2.41 billion Chinese Renmimbi.
This was the third consecutive year of growth at Shandong Lukang Pharmaceutical.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Shandong Lukang Pharmaceutical had sales
of 2.33 billion Chinese Renmimbi.
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
61.8% in 2016, from
56.60 million Chinese Renmimbi to 91.61 million Chinese Renmimbi.
Shandong Lukang Pharmaceutical also saw significant increases in sales in
Veterinary Antibiotic (up 13.6% to 687.92 million Chinese Renmimbi)
Other Operation (up 9.3% to 36.25 million Chinese Renmimbi)
Not all segments of Shandong Lukang Pharmaceutical experienced an increase in sales in 2016:
sales of Human Antibiotic fell 1.5% to 1.69 billion Chinese Renmimbi.